Steven Breazzano
Contributor since: 2010
Latest Articles
Taro Pharmaceuticals: Last Week's Move Is Only The Beginning
Prothena: Recent Sell-Off On Positive Data Creates Buying Opportunity
Ignyta: Now Public With A Targeted Oncology Pipeline Poised For Success
Keryx Biopharmaceuticals: Grim Realities Of The Dialysis Market Will Result In Commercial Failure
Sarepta Therapeutics: Underappreciated Clinical And Regulatory Risk Following Analysis Of Prosensa Failure
Sorrento Therapeutics: Abbreviated Path Through The FDA To Fuel Profits
What Does The FDA's Breakthrough Designation Mean For Investors?
Aratana Therapeutics: Innovative Business Model Providing Effective Medicines For Pets And Profits For Investors
Mirati Therapeutics: Revamped And Ready To Go With A Targeted Oncology Pipeline
What The Snubbing Of Hyaluronic Acid By The AAOS Means For Investors
Obesity Sector Update And Compelling Short Opportunity
4 Biotechs Targeting Fibrosis
Raptor Pharmaceuticals: Stock Below Fair Value With Recent Pullback
NPS Pharmaceuticals: Misunderstood Assets And Compelling Value Play
Seattle Genetics Shares Continue To Impress - And It's Not Too Late To Buy
Not All Biotechnology ETFs Created Equal
Protalix BioTherapeutics Finally Receives FDA Approval To Market Elelyso For Enzyme Replacement Therapy In Gaucher's Disease
Coronado Biosciences: What Do The Recent Trial Changes Mean For Investors?
LPath's Form / Fill Delay Disappoints Investors: Long-Term Buying Opportunity?
Coronado Biosciences: Phase II Trials Provide Multiple Shots On Goal
Biotech Class Of 2010: IPOs Revisited
Seattle Genetics: Innovative Biotech, Speculative Stock
Protalix BioTherapeutics: FDA Delay Provides Attractive Entry Point
Prolor Biotech: De-Risked And Ready To Begin Phase 3 Trials
DUSA Pharmaceuticals Shares Tumble After Earnings: Low Growth Ahead?
LPath Investors Have iSONEP Trial Results In Sight
Raptor Pharmaceuticals Provides Update On Lead Candidate: RP103
Savient Pharmaceuticals: Value Play Or Value Trap?
Raptor Pharmaceuticals Announces Positive Phase 3 Trial Results: Shares Tumble
iBio: Recent Lull Offers Opportunity to the Patient Investor
Biotech Valuation Part 2: Market Size and rNPV Applied to Prolor Biotech
Biotech Valuation Part 1: Science, Patents, and Management